Sai Parenterals Sees 64% PAT Jump to ₹17 Crore in FY26 Driven by CDMO Growth

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Sai Parenterals Sees 64% PAT Jump to ₹17 Crore in FY26 Driven by CDMO Growth
Overview

Sai Parenterals reported a strong fiscal year 2026, with its standalone Profit After Tax (PAT) jumping 64% to ₹17 crore. The company's Contract Development and Manufacturing Organization (CDMO) segment showed exceptional growth, and proceeds from its IPO are being used to expand manufacturing capabilities.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Sai Parenterals Reports Strong FY26 Performance with 64% PAT Growth

Sai Parenterals Limited announced significant financial results for the fiscal year ending March 31, 2026 (FY26). The company's standalone Profit After Tax (PAT) surged by 64% year-over-year, reaching ₹17 crore, up from ₹10 crore in FY25. Standalone revenue also saw a healthy increase of 31%, totaling ₹162 crore for the period.

Key Growth Drivers

On a consolidated basis, Sai Parenterals reported total revenue of ₹381 crore for FY26. A major contributor to this performance was the company's Contract Development and Manufacturing Organization (CDMO) segment, which experienced explosive growth with revenues increasing by over 250% compared to the previous year. This rapid expansion in the CDMO sector highlights its increasing importance to the company's overall financial health.

Strategic Expansion Funded by IPO

The company is actively utilizing the ₹285 crore raised from its Initial Public Offering (IPO) in March 2026. These funds are earmarked for critical strategic initiatives, including expanding manufacturing capacities across several facilities, establishing a new Research and Development (R&D) center, repaying debt, and bolstering working capital. The upgrades to manufacturing facilities are expected to be completed between October 2026 and July 2027.

Acquisition Boosts Consolidated Figures

Sai Parenterals also acquired a 74.6% stake in Noumed Pharmaceuticals (Australia/New Zealand) in November 2025, leading to the consolidation of its financial results since that time. This acquisition is expected to contribute to the company's consolidated financial performance.

Looking Ahead: Risks and Focus Areas

Investors will be closely watching the execution of the planned manufacturing and R&D facility expansions, focusing on adherence to timelines and budgets. The successful integration and performance of Noumed Pharmaceuticals will also be a key factor in evaluating the company's consolidated results. Sustaining the momentum in the CDMO segment and contributions from international operations will be critical performance indicators for Sai Parenterals moving forward.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.